- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00129428
Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix
The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Keloid, scleroderma, acne keloidalis nuchae, and burn scars are all characterized by collagenous thickening of the skin resulting in superficial and deep cutaneous sclerosis. Treatments for these disabling conditions are inadequate at present. Recently, in non-controlled studies, UVA1 was shown to induce improvement in patients with scleroderma, granuloma annulare and urticaria pigmentosa.
However, UVA1 is unable to penetrate pigmented skin at an effective level to activate matrix metalloproteinases (MMPs). The investigators' preliminary data show that high dose UVB (160 mJ/cm2) will penetrate pigmented skin and activate the cellular pathways necessary to stimulate MMPs. They postulate, therefore, that in pigmented skin, higher than usual UVB doses can improve these fibrosing skin conditions safely through collagenase-mediated removal of excess dermal collagen via activation of MMP pathways.
The purpose of this research project is to study the effectiveness of high dose UVB (290-320nm at up to 320mJ/cm2) irradiation for the treatment of skin conditions with altered dermal matrix in patients with increased skin pigmentation. These disorders include but are not limited to keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, and granuloma annulare. Up to fifty patients with one of these diagnoses or related conditions will receive UVB irradiation up to 5 times per week, for 16 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- In good general health and between 10-80 years of age.
- Willing and able to receive UVB, as directed in the protocol; make evaluation visits; follow protocol restrictions; and sign a written, witnessed, informed consent form.
- Have a clinical diagnosis of keloid, scleroderma, old burn scars, granuloma annulare, or acne keloidalis nuchae.
- No disease states or physical conditions that would impair evaluation of the test site
- Must live within a reasonable driving distance of Ann Arbor, Michigan, and/or be able to attend all of the scheduled appointments during the study.
Exclusion Criteria:
- Have a history of photosensitivity (development of hives or bumps with exposure to light) or experience hypersensitivity in a UVB photo-provocation test.
- Have participated in another investigational study in the past 4 weeks, taken oral therapy for skin condition, or on photosensitizing medications.
- Pregnant, nursing, or planning to become pregnant during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: UVB Irradiation
A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
|
A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement in appearance of keloids (hypertrophic scars), scleroderma, acne keloidalis nuchae,old burn scars, granuloma annulare, and related conditions with altered dermal matrix
Time Frame: Subjects will be evaluated at weeks 1, 2, 4, and then at monthly intervals until the end of the study.
|
Subjects will be evaluated at weeks 1, 2, 4, and then at monthly intervals until the end of the study.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assays to be performed on biopsy specimens may include any or all of the following assays: in situ hybridization, immunohistologic analysis, in situ zymography, radioimmunoassay, and Western blot analysis
Time Frame: Assays will be performed after specimen collection
|
Assays will be performed after specimen collection
|
Photographs will also be taken.
Time Frame: At baseline and at end of the study.
|
At baseline and at end of the study.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Connective Tissue Diseases
- Fibrosis
- Acneiform Eruptions
- Cicatrix
- Hair Diseases
- Collagen Diseases
- Necrobiotic Disorders
- Folliculitis
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Skin Diseases
- Granuloma
- Scleroderma, Localized
- Keloid
- Granuloma Annulare
- Acne Keloid
Other Study ID Numbers
- Derm 447
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scleroderma, Localized
-
University of CologneRecruitingLocalized SclerodermaGermany
-
Cairo UniversityUnknownLocalized SclerodermaEgypt
-
Castle Creek Biosciences, LLC.TerminatedScleroderma, Localized | Morphea | SclerodermaUnited States
-
University Children's Hospital, ZurichCompleted
-
Northwestern UniversityTerminated
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
Lawson Health Research InstituteNovartis PharmaceuticalsTerminated
-
BiocadRecruitingSystemic SclerodermaRussian Federation
-
Rennes University HospitalCompleted
-
University of UtahEnrolling by invitationSclerodermaUnited States
Clinical Trials on UVB Irradiation
-
University of MichiganTerminatedPsoriasis | Mycosis Fungoides | Atopic Dermatitis | Alopecia | Urticaria | Stretch Marks | DermatosesUnited States
-
University Hospital, GrenobleCommissariat A L'energie AtomiqueCompleted
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompleted
-
University Hospital MuensterCompleted
-
Rockefeller UniversityCompletedAtopic DermatitisUnited States
-
Medical University of GrazCompleted
-
Johns Hopkins UniversityCompleted
-
Wake Forest UniversityCompleted
-
Rockefeller UniversityDoris Duke Charitable FoundationTerminatedChronic Plaque PsoriasisUnited States
-
University of DundeeNHS TaysideCompletedAtopic EczemaUnited Kingdom